Pharma Merger

     WILMINGTON, Del. – Directors are selling Kythera Biopharmaceuticals too cheaply through an unfair process to Allergan, in a cash ($50) and stock ($15) deal valued at $1.9 billion, shareholders claim in Chancery Court.

%d bloggers like this: